Background. Up to 44% of women who experience a urinary tract infection (UTI) develop a recurrent infection (rUTI) within one year. Insufficient evidence about risk factors for recurrence limits clinicians' ability to identify women at risk for rUTI who may benefit from further interventions.
Background. The optimal approach for treating outpatient male urinary tract infections (UTI) is unclear. We studied the current management of male UTI in private outpatient clinics, and evaluated antibiotic choice, treatment duration, and the outcome of recurrence of UTI.
Methods. Visits for all male patients 18 years of age and older during 2011-2015 with ICD-9 Codes for UTI or associated symptoms were extracted from the EPIC Clarity Database of two family medicine, two urology and one internal medicine clinics. For each eligible visit in which an antibiotic was prescribed, we extracted data on the antibiotic used, the duration of treatment, recurrent UTI episodes, as well as patient medical and surgical history. Urologic anatomic abnormalities were an exclusion criterion (Figure 1) .
Results. Six hundred thirty-seven eligible visits were included for 573 unique patients (mean age 53.7 (±16.7 years)). Fluoroquinolones (FQs) were the most commonly prescribed class of antibiotic (69.7%), followed by trimethoprim-sulfamethoxazole (TMP-SMX) (21.2%), nitrofurantoin (5.3%) and β-lactams (3.8%). Use of FQ was lower in the age group of 55 years and above than <55 years (65.4% vs. 74.6% respectively, P < 0.01). Visits in the urology department were less likely to be treated with TMP-SMX, but more likely to be treated with a β-lactam. Those with a higher Charlson Comorbodity Index were more likely to be treated with β-lactams. Nitrofurantoin use was higher for men 55 years of age and above compared with those younger (7.4% and 3% respectively, P <0.01). Overall, the rate of recurrence was 5.6%. Recurrence was not significantly different between longer (>7 days) and shorter (≤7 days) treatments. In the multiple regression analysis, predictors of longer treatment duration included presence of complicating factors (pyelonephritis, nephrolithiasis or prostatitis), use of nitrofurantoin or β-lactams, and visits seen in urology. The presence of fever, diabetes, and BPH, as well as patient race, were not associated with antibiotic choice or treatment duration.
Conclusion. Men with UTIs are most frequently prescribed FQ. Providers' choice of antibiotic was influenced by patient age and comorbidities, while treatment duration was influenced by presence of complicating factors. Background. A significant percentage of patients admitted to the hospital with UTI are infected with ESBL positive and quinolone-resistant (FQ NS) enterobacteriaceae (ENT) that can complicate patient outcomes due to potentially inadequate antibiotic therapy. We used a large national multicenter database to ascertain the demography associated with susceptible and resistant UTI and the underlying comorbidities.
Patient Demographics and Comorbidity Profiles Associated with Hospitalized Patients Admitted with Resistant vs. Susceptible Urinary Tract Infections (UTIs): A Multicenter Analysis
Methods. We analyzed the first positive ENT urine culture ≤3 days from admission in those with a discharge primary or secondary UTI ICD10 code from 68 US hospitals from October 1, 2015 -2017 . Patient demographics were identified using AHRQ classifications to assess for specific risk factors and categorized by ESBL and FQ resistance status. Healthcare-associated (HCA) episodes were defined as admissions from another care facility, admission in the prior 30 days, and presence of dialysis or cancer comorbidity. The Fisher's exact test was used to test for significance.
Results. Of 16,022 adults (mean age 69.5 years; 77.7% female) with culture positive ENT UTI were identified; 11.0% (n = 1,763) were ESBL +, 31.3% (n = 5,017) were FQ NS and 8.9% (n = 1,433) being both ESBL + and FQ NS. Admissions with ESBL + /FQ NS were significantly more likely to be male, admitted with HCA risk factors and with higher important comorbidities. 
